Website
Genetic Signatures Ltd.Telephone
61.2.9870.7580
Address
7 Eliza Street Newtown, New South Wales (NSW) 2042
Description
Genetic Signatures Ltd. is a research company, which engages in the identification and commercialization of individual genetic signatures for the diagnosis of infectious diseases. It is also involved in the sale of associated products into the diagnostic and research marketplaces. Its products include the treatment for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. It operates in the following geographical segments: Asia Pacific, Europe, Middle East, and Africa (EMEA), and Americas. The company was founded by Robert J. Birrell, Christopher M. Abbott, and Geoffrey Grigg on February 15, 2001 and is headquartered in Newtown, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.44 - 0.85
Trade Value (12mth)
AU$21,243.00
1 week
-3.12%
1 month
-3.12%
YTD
-6.06%
1 year
31.91%
All time high
2.87
EPS 3 yr Growth
-1000.80%
EBITDA Margin
-207.10%
Operating Cashflow
-$10m
Free Cash Flow Return
-19.30%
ROIC
-34.10%
Interest Coverage
-577.80
Quick Ratio
8.80
Shares on Issue (Fully Dilluted)
210m
HALO Sector
Industrials
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
17 December 24 |
Application for quotation of securities - GSS
×
Application for quotation of securities - GSS |
17 December 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
09 December 24 |
Notification regarding unquoted securities - GSS
×
Notification regarding unquoted securities - GSS |
27 November 24 |
Notification of cessation of securities - GSS
×
Notification of cessation of securities - GSS |
25 November 24 |
Application for quotation of securities - GSS
×
Application for quotation of securities - GSS |
22 November 24 |
$5m R&D Tax Incentive Received
×
$5m R&D Tax Incentive Received |
20 November 24 |
2024 AGM Chairman's Address and CEO Presentation
×
2024 AGM Chairman's Address and CEO Presentation |
20 November 24 |
AGM Results of Meeting
×
AGM Results of Meeting |
20 November 24 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
31 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
18 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
14 October 24 |
Notification regarding unquoted securities - GSS
×
Notification regarding unquoted securities - GSS |
01 October 24 |
Initial Director's Interest Notice - Anne Lockwood
×
Initial Director's Interest Notice - Anne Lockwood |
01 October 24 |
Initial Director's Interest Notice - Jenny Harry
×
Initial Director's Interest Notice - Jenny Harry |
20 September 24 |
Board Composition Update
×
Board Composition Update |
20 September 24 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
18 September 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
05 September 24 |
Application for quotation of securities - GSS
×
Application for quotation of securities - GSS |
05 September 24 |
Notification of cessation of securities - GSS
×
Notification of cessation of securities - GSS |
30 August 24 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
30 August 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
22 August 24 |
Changes to Genetic Signatures' Board of Directors
×
Changes to Genetic Signatures' Board of Directors |
22 August 24 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
05 August 24 |
Notification of cessation of securities - GSS
×
Notification of cessation of securities - GSS |
31 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.